Physician profile
Muhammad Mirza
NPI 1568561678
$64,507.22
in general payments reported to CMS, 2019-2025
60 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $5,001 · 2021: $1,454 · 2022: $8,912 · 2023: $8,107 · 2024: $5,033 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $4,527 · Food and Beverage: $2,483 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,158.00 |
| Travel and Lodging | $4,527.31 |
| Food and Beverage | $2,482.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42,434.17 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Incyte Corporation | $6,564.75 | 2019-2024 | |
| Avyxa Pharma, LLC | $4,198.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,735.56 | 2019-2024 | |
| Globus Medical, INC. | $1,090.14 | 2023 | Excelsius3d Imaging System, Excelsiusgps Robotic Navigation System |
| Aveo Pharmaceuticals, INC. | $1,089.06 | 2021-2022 | |
| Daiichi Sankyo INC. | $671.84 | 2020-2025 | Vanflyta |
| Beigene USA, INC. | $525.00 | 2022 | |
| Gilead Sciences, INC. | $496.53 | 2019-2025 | Trodelvy |
| Celgene Corporation | $348.15 | 2019-2024 | Reblozyl, Opdualag |
| Genzyme Corporation | $297.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $261.49 | 2021-2023 | Jemperli, Ojjaara |
| Dova Pharmaceuticals | $250.37 | 2020 | |
| Abbvie INC. | $245.33 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $236.73 | 2019-2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.